

2026 ASTCT Fundamentals of HCT Virtual Training Course

April 9, 2026 - April 10, 2026

TARGET AUDIENCE

The target audience for this activity includes hematology/oncology and transplant pharmacists, pharmacy residents, physicians, fellows, hospitalists, nurse practitioners, physician assistants, and nurses who are involved in delivering quality HCT/cellular immunotherapy healthcare in hospital or clinic settings.

PROGRAM OVERVIEW

The Fundamentals of HCT Training Course is a 2-day conference that provides a broad overview and introduction of hematopoietic cell transplantation (HCT), also referred to as blood and marrow transplantation (BMT), as well as cellular immunotherapy (CI). Throughout the lectures, participants will be introduced to numerous aspects of the HCT-CI processes, which are designed to develop or enhance skills required in the management of patients undergoing these procedures. This course incorporates case-based learning to emphasize application of concepts taught through didactic lecture with a strong focus on the pharmacotherapeutic management.

The Fundamentals of HCT Training Course is designed to inform attendees about the latest developments in 1) treatment guidelines; 2) therapeutic regimens; 3) diseases state management; 4) supportive care therapies; 5) controversial care issues; and 6) clinical trial data.

LEARNING OBJECTIVES

- Discuss current clinical practice and challenges for healthcare professionals in the field of hematopoietic cell transplantation (HCT) and cellular immunotherapy
- Identify best practice strategies and clinical challenges related to conditioning, donor selection and HLA typing, supportive care in the peri-transplant period, immune effector cell therapy, gene therapy, tumor infiltrating lymphocytes and T-cell receptor therapy for solid tumors, viral infections, fungal infections, acute graft versus host disease, chronic graft versus host disease, veno-occlusive disease/sinusoidal obstruction syndrome, thrombotic microangiopathy, geriatrics, and pediatrics
- Review patient cases related to caring for HCT patients to augment the didactic lectures and examine case-based presentations on rare complications post immune effector cell therapy and navigating cytopenias post-transplant and graft failure

INSTRUCTIONS FOR PARTICIPATION AND REQUESTING CREDIT

There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CE information, completing the activity, and completing the evaluation form.

Credit Fulfillment

- If you are requesting AMA credits, ANCC credits, or a certificate of participation, your certificate will be available for download.
- If you are a pharmacist requesting ACPE credits, your credit request will be uploaded to CPE Monitor within 60 days after the activity.

Note: There is ONE evaluation for the entire program, not one for each individual session. A link for the CE evaluation will be provided post-conference.

Technical Requirements: <http://www.francefoundat ion.com/general-requirements.html>

ACCREDITED PROVIDER

This activity is jointly provided by The France Foundation and the American Society for Transplantation and Cellular Therapy (ASTCT).



Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by The France Foundation and the American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CREDIT DESIGNATION

The France Foundation designates this live activity for a maximum of 15.0 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES

The France Foundation designates this activity for 15.0 contact hours.

PHARMACISTS

This knowledge and application-based activity qualifies for 15.0 contact hours (0.150 CEUs) of continuing pharmacy education credit. **Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date.** Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

All other health care professionals completing this course will be issued a statement of participation.

PLANNING COMMITTEE

Kendall Shultes – VA Tennessee Valley Healthcare System
Sara Leidy – The University of Kansas Health System
Mallori Lynn Anderson – MD Anderson
Alyssa Donadio – Miami Cancer Institute
Amanda Strommen – Children’ Hospital Colorado
Vera Pervitsky – Oregon Health and Science University
Katie Karkowski – Dartmouth Health
Mary McGann – Medical University of South Carolina
Alyson Vezina – Orlando Health Arnold Palmer Hospital for Children
Jinjoo Kang – Northwell Health
Emma Sheldon – Scripps Health
Susie Long – University of Minnesota Masonic Children’s Hospital
Kun (Peter) Lin – Northwestern Memorial Hospital
Danae Beckman – The University of Kansas Medical Center
Michael Williams – Aurora St. Luke’s Medical Center
Ashley Jones – UT Southwestern Medical Center
Samantha Maples – Allegheny Health Network
Michelle Skinner – Oregon Health and Science University

Program Agenda

Thursday, April 9th, 2025 (CST)	Topic		UAN #
8:00 – 8:10 AM CST (10)	Welcome – Opening Remarks Kendall Shultes, PharmD, BCOP		-
8:10 – 8:55 AM CST (45) – 0.75	Introduction to Hematopoietic Cell Transplantation Jason Ernstberger, PharmD, BCOP University of Cincinnati Medical Center, Cincinnati, OH		JA0007204-9999-26-045-L01-P
9:00 – 10:00 AM CST (60) – 1.0	Donor Selection and Introduction to HLA Typing Adult – Shatha Farhan, MD Henry Ford Health System, Detroit, MI Pediatric – Anand Srinivasan, MBBS Mayo Clinic, Rochester, MN		JA0007204-9999-26-063-L01-P
10:00 – 10:10 AM CST (10)	Break		-
10:10 – 11:10 AM CST (60) – 1.0	Principles of Conditioning in Hematopoietic Cell Transplantation Binni Kunvarjee, PharmD, BCOP Memorial Sloan Kettering Cancer Center, New York, NY		JA0007204-9999-26-046-L01-P
11:15 – 12:15 PM CST (60) – 1.0	Supportive Care for Peri-Transplant Complications Amber Clemmons, PharmD, BCOP, FHOPA Wellstar-MCG Health Medical Center, Augusta, GA		JA0007204-9999-26-047-L01-P
12:15 – 12:35 PM CST (20)	Lunch		-
12:35 – 1:20 PM CST (45) – 0.75	Special Populations in HCT: Pediatrics Susie Long, PharmD University of Minnesota Masonic Children’s Hospital, Minneapolis, MN	Special Populations in HCT: Geriatrics Andrew Artz, MD, MS City of Hope, Duarte, CA	Pediatrics: JA0007204-9999-26-048-L01-P Geriatrics: JA0007204-9999-26-049-L01-P
1:25 – 2:10 PM CST (45) – 0.75	Caring for the AYA HCT Patient: It takes a Village – Interdisciplinary Panel		JA0007204-9999-26-050-L01-P
	Stephanie Fooks-Parker MSW, LSW, OSW-C Social Worker Children’s Hospital of Philadelphia, Philadelphia, PA	Tiffany Harmer, BSN, RN Cellular Therapy & BMT Nurse Coordinator Huntsman Cancer Institute, Salt Lake City, UT	
2:10 – 2:20 PM CST (10)	Break		-
2:20 – 3:20 PM CST (60) – 1.0	Immune Effector Cell Products and Indications Jennifer Collins, PharmD, BCOP University of Chicago Medicine, Chicago, IL		JA0007204-9999-26-051-L01-P
3:25 – 4:25 PM CT (60) – 1.0	Immune Effector Cell Management of Toxicities and Complications Cameron Ninos, PharmD, BCOP University of Wisconsin Madison, Madison, WI		JA0007204-9999-26-052-L01-P
4:25 – 4:55 PM CT (30)	Virtual Roundtable Discussion & Wrap-Up (*No CE provided)		N/A
Total Credit Day 1 = 7.25			

Friday, April 10 th , 2025 (CST)	Topic		
8:00 – 9:00 AM CST (60) – 1.0	Fungal Infections in HCT Aliyah Baluch, MD Moffitt Cancer Center, Tampa, FL		JA0007204-9999-26-053-L01-P
9:05 – 10:05 AM CST (60) – 1.0	Viral Infections in HCT LeAnne Kennedy, PharmD, BCOP, CPP, FHOA, FASTCT Atrium Health Wake Forest Baptist, Winston-Salem, NC		JA0007204-9999-26-054-L01-P
10:05 – 10:15 AM CST (10)	Break		-
10:15 – 11:00 AM CST (45) – 0.75	Thrombotic Microangiopathy in Hematopoietic Cell Transplantation Hemalatha Rangarajan, MD Nationwide Children's Hospital, Columbus, OH	Veno Occlusive Disease/ Sinusoidal Obstructive Syndrome Teresa Rushing, PharmD, BCPS, BCOP Children's Hospital Los Angeles, Los Angeles, CA	Thrombotic: JA0007204-9999-26-055-L01-P Veno Occlusive: JA0007204-9999-26-056-L01-P
11:05 – 12:20 PM CST (75) – 1.25	Acute Graft versus Host Disease Elizabeth DiMaggio, PharmD, BCOP Moffitt Cancer Center, Tampa, FL		JA0007204-9999-26-057-L01-P
12:20 – 12:30 PM CST (10)	Lunch		-
12:30 – 1:45 PM CST (75) – 1.25	Chronic Graft versus Host Disease Rebecca Gonzalez, PharmD, BCOP Moffitt Cancer Center, Tampa, FL		JA0007204-9999-26-058-L01-P
1:45 – 1:55 PM CST (10)	Break		-
1:55 – 2:40 PM CST (45) – 0.75	Patient Case: Rare Complications Post-IEC Therapy: Neurological Toxicity and GI Enterocolitis Bettina Zerante, APP University of Chicago Medical Center, Chicago, IL	Patient Case: Navigating Cytopenias Post Transplant and Graft Failure Forat Lutfi, MD University of Kansas Medical Center Westwood, KS	Rare Complications: JA0007204-9999-26-059-L01-P Navigating Cytopenias: JA0007204-9999-26-060-L01-P
2:45 – 3:45 PM CST (60) – 1.0	Tumor Infiltrating Lymphocytes and T-Cell Receptor Therapy for Solid Tumors Daniel Olson, MD University of Chicago Medical Center, Chicago, IL		JA0007204-9999-26-061-L01-P
3:45 – 3:55 PM CST (10)	Break		-
3:55 – 4:40 PM CST (45) – 0.75	Cellular Therapy and Gene Therapy for Non-Malignant Indications Christine Duncan, MD Boston Children's Cancer and Blood Disorders Center, Boston, MA		JA0007204-9999-26-062-L01-P
4:40 – 5:10 PM CST (30)	Virtual Roundtable Discussion & Wrap-Up (*No CE provided)		N/A
Total Credit for Day 2 = 7.75			

DISCLOSURE POLICY

The France Foundation (TFF) and The American Society for Transplantation and Cellular Therapy (ASTCT) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.

Disclosures for members of the planning committee and faculty will be disclosed to learners prior to the conference and can also be found [here](#).

Disclosure of Unlabeled Use:

The France Foundation (TFF) and The American Society for Transplantation and Cellular Therapy (ASTCT) require CE faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational. They must also disclose limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Disclaimer:

The France Foundation and the American Society for Transplantation and Cellular Therapy present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, The American Society for Transplantation and Cellular Therapy, and the commercial supporter(s) assume no liability for the information herein.

CONTACT INFORMATION

If you have questions about this CME/CE activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.